LEXXW - Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
(TheNewswire)
-
25 th patent grant is Lexaria’s first-everpatent for the enhanced delivery of antivirals
Kelowna, British Columbia – TheNewswire - April 21, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or“Lexaria”), a global innovator in drug delivery platformsannounces the Company is receiving its first-ever patent for the useof DehydraTECH technology in the enhanced delivery of antiviraldrugs.
Lexaria has received notification from the UnitedStates Patent and Trademark Office that patent 11,311,559 for Compositions and Methods ForEnhanced Delivery Of Antiviral Agents will beissued to the Company on April 26, 2022.
"This will be our 25th patent granted worldwideand another validation of the versatility of our DehydraTECH drugdelivery technology," said Chris Bunka, CEO of Lexaria."This new patent adds to our existing suite of granted patents inthe EU, the U.S., India, Japan and Australia, and continues to buildvalue for Lexaria shareholders and clients.”
Lexaria previouslyannounced that remdesivir andebastine processed with DehydraTECH were effective at inhibiting theCOVID-19/SARS-CoV-2 virus using an in vitro screening assay ininfected cells in study VIRAL-C21-3. Lexaria separatelydemonstrated that antiviral drugsprocessed with DehydraTECH were able to reach peak blood concentrationlevels that were double those of non-DehydraTECH-processed; andoverall volumes of drug delivered into bloodstream were up to triplethe amount compared to non-DehydraTECH-processed drugs.
As evidenced with other drugs that Lexaria hasinvestigated, the award of intellectual property protection is a keystep towards ultimately monetizing Lexaria’s revolutionaryDehydraTECH drug delivery technology. This is Lexaria’s 25th grantedpatent and the 10th granted in the U.S. Lexaria continues to file newpatent applications as its research and development programs uncovernew discoveries.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting more effectiveoral delivery. Since 2016, DehydraTECH has repeatedly demonstrated theability to increase bio-absorption with cannabinoids and nicotine by5-10x and, in some instances with cannabinoids by as much as 27xcompared to standard industry formulations, reduce time of onset from1 - 2 hours to minutes, and mask unwanted tastes; and is also beingevaluated for orally administered antiviral drugs, non-steroidalanti-inflammatory drugs (NSAIDs), PDE5 inhibitors and more.DehydraTECH has also evidenced an ability to deliver some drugs moreeffectively across the blood brain barrier. Lexaria operates alicensed in-house research laboratory and holds a robust intellectualproperty portfolio with 25 patents granted and over 50 patents pendingworldwide. For more information, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS
This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the company relating the Company’sability to carry out research initiatives, receive regulatoryapprovals or grants or experience positive effects or results from anyresearch or study. Such forward-looking statements are estimatesreflecting the Company's best judgment based upon current informationand involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which couldcause actual results to differ materially from those estimated by theCompany include, but are not limited to, government regulation andregulatory approvals, managing and maintaining growth, the effect ofadverse publicity, litigation, competition, scientific discovery, thepatent application and approval process, potential adverse effectsarising from the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements contained herein, whether as a result of any newinformation, future events, changed circumstances or otherwise, exceptas otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of InvestorRelations
Copyright (c) 2022 TheNewswire - All rights reserved.